Poolbeg Pharma Plc is a clinical-stage biopharmaceutical company, which focuses on the development of innovative medicines to address unmet medical needs. The firm is focused on the development of medicines to address unmet medical needs. Its clinical programmes target addressable markets, including cancer immunotherapy-induced Cytokine Release Syndrome (CRS) and metabolic conditions, such as obesity with the development of an oral encapsulated glucagon-like peptide (GLP-1R) agonist. Its pipeline includes POLB 001 Oncology, POLB 001 Influenza, AI Programmes and Oral Encapsulated GLP-1programme. POLB 001 is an orally delivered p38 MAP Kinase inhibitor being developed for the prevention of CRS associated with Bispecific Antibodies and CAR T immunotherapy treatments in cancer. The company uses artificial intelligence to identify infectious disease drug targets & treatments. The Oral Encapsulated GLP-1 programme leverages an advanced delivery system that encapsulates active pharmaceutical ingredients using Generally Regarded as Safe (GRAS) components.
Follow-Up Questions
Poolbeg Pharma PLC의 CEO는 누구입니까?
Dr. Jeremy Skillington은 2021부터 회사에 합류한 Poolbeg Pharma PLC의 Chief Executive Officer입니다.
POLBF 주식의 가격 성능은 어떻습니까?
POLBF의 현재 가격은 $0이며, 전 거래일에 decreased 0% 하였습니다.
Poolbeg Pharma PLC의 주요 사업 주제나 업종은 무엇입니까?
Poolbeg Pharma PLC은 Pharmaceuticals 업종에 속하며, 해당 부문은 Health Care입니다
Poolbeg Pharma PLC의 시가총액은 얼마입니까?
Poolbeg Pharma PLC의 현재 시가총액은 $0입니다
Poolbeg Pharma PLC는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 5명의 분석가가 Poolbeg Pharma PLC에 대한 분석 평가를 실시했으며, 이는 1명의 강력한 매수, 3명의 매수, 1명의 보유, 0명의 매도, 그리고 1명의 강력한 매도를 포함합니다
